GHP Q3 2021

50 GHP / Q3 2021 GHP / Q3 2021 51 , , Jun21268 May21575 Pioneering Varicose Vein Treatments Award-winning TheWhiteley Clinic introduced non-surgical varicose vein treatments to the United Kingdomwhen its founder, ProfessorMarkWhiteley performed the first endo-venous (non-surgical) varicose vein operation in the UK inMarch 1999. ProfessorWhiteley has been at the forefront of innovation in varicose vein treatments ever since and his clinic has now been recognised as Best for Varicose Vein Treatments 2021 – UK by Global Health & Pharma magazine. Join us as we take a closer look. In 2001, Professor Whiteley invented Transluminal Occlusion of Perforators (TRLOP) with Judy Holdstock, a technique to close perforating veins, and was the first in Europe to perform Microwave Ablation of Varicose Veins in February 2019. In addition to this, he was the first in the world to perform HIFU (Sonovein) treatment of varicose veins commercially. “We are internationally recognised for our research into investigating and treating varicose veins, venous leg ulcers and pelvic congestion syndrome,” Mark explains. “Having spent two decades studying these, including over a hundred peer-reviewed research papers, five books, several national and international prizes and several PhDs, we now understand veins in a way they have never been understood before.” Mark has been campaigning for 16 years to try and get patients with venous leg ulcers to be treated with endo-venous techniques. Randomised controlled trials have shown this to be the optimal way of treating leg ulcers rather than the usual compression bandaging. “Not only would it save the country £1-3 billion per year, but it would also improve patients’ quality of life and not surprising, it is already NICE guidelines although nobody seems to follow them,” states Mark, who has written a book for patients and relatives to help them understand this approach called Leg Ulcer Treatment Revolution. Mark and his team are recognised as world leaders in the treatment of pelvic congestion syndrome, and Mark even wrote the first book on this subject for patients called Pelvic Congestion Syndrome – Chronic Pelvic Pain and Pelvic Venous Disorders. Alongside this, Mark has also introduced aesthetic phlebology (the treatment of veins on the face, breasts, hands, arms and feet) and has recently patented a new technique for treating vertical bulging veins on the forehead. He and his colleague from Brazil have written the first ever research paper showing how these can be treated successfully. Ever since the Bristol heart scandal, it has been known that patients will only be confident that doctors are getting good results, and the techniques they use are appropriate, if doctors and patients complete an ongoing registry in that condition. There are now many registries for heart disease, obesity surgery, major joint surgery, cancer, etc. “This is why myself and The Whiteley Clinic are founding members of The College of Phlebology Venous Registry,” said Mark. “This registry will allow patients to check medium and long-term outcomes, ensuring that they know their treatments at The Whiteley Clinic will provide excellent long-term results.” Meanwhile, over the last 18 months, the biggest challenge for The Whiteley Clinic has been the COVID-19 pandemic, but it found a solution. As a medical facility, it was able to develop a COVID-secure protocol relatively quickly which was approved by an independent infection-control company. In addition, the Clinic was awarded the COVID-secure badge by the medical insurer, BUPA. Prior COVID, the Clinic was actively planning further expansion within the UK and had attracted interest from several potential investors, and they are all hoping to pick up where they left off. Mark states, “Our research projects are proceeding to ensure that we remain at the top of venous surgery in the world and as we settle into the new post-COVID norm, we expect to resume our growth and expansion first in the UK and beyond.” Contact: Professor Mark Whiteley Email: [email protected] Website: Intelligence, Quality, Empathy iQ Biosciences is a global provider of focused research to the pharmaceutical, biotechnology, and diagnostic industries in the formof intelligent research services and quality biospecimens. Taking reliability to the next level, iQ Biosciences excels at being a trusted partner in the biomedical community to help cure disease. Global Health & Pharmamagazine has recognised this with its award for Best Biospecimens Provider and Research Services Company 2021 – USA. iQ Biosciences believes that it is an urgent matter to help the biomedical research community deliver on therapeutic promises, and that all researchers should have access to the highest standards of testing services and investigative approaches for qualitatively assessing or quantitively measuring their test compound’s bioactivity at practical prices. The company has three core values – intelligence, quality, and empathy – which represent how it wants to behave, as individuals and as an organisation. ‘Intelligence’ is about valuing comprehensive communication, strategic planning, and thoughtful problem solving; ‘quality’ means it strives for its work to reflect the quintessence of integrity, consistency, and efficiency; and ‘empathy’ highlights its knowledge that research is important and how it is grateful to be part of a team that is advancing research and helping develop therapies for many devastating diseases. iQ Biosciences’ offering includes research testing, drug discovery, and preclinical studies which can help determine a product’s safety and mechanism of action. These services include testing, in-vitro based safety assays, and functional characterisation using in-vitro assays or in-vivo pharmacology models. Primary cells, such as peripheral blood mononuclear cells (PBMCs), splenocytes, and bone marrow cells are frequently used as a valuable research tools for in-vitro work. iQ Biosciences obtains human and non-human source tissues from well-respected institutions and isolates the relevant cell types through careful processing. It offers high-quality samples from a diverse group of animal species that are pertinent for many different applications in drug development or academic research. Just a few of these applications include characterising mechanism of action, determining cross-reactivity, and safety assessment. When developing an antibody therapeutic, it is critical to know its potential for inducing a cell- mediated immune defence such as ADCC or ADCP. Primary cells including NK cells and monocytes are useful for in-vitro studies to characterise mechanism of action of the therapeutic. For some therapeutic modalities, it’s important to characterise cross-reactivity across species. It’s also common practice for safety, effectiveness, and binding studies. In-vivo animal studies are expensive, so in-vitro validation with animal primary cells is a wise and cost- conscious approach. Toxicity assessment is a requirement prior to proceeding to clinical trials with the therapeutic. Cryopreserved PBMCs are frequently used for in-vitro safety studies such as the cytokine release assay, where the PBMCs are thawed and stimulated with the molecule prior to cytokine measurement. iQ Biosciences is committed to operating under the highest ethical and legal standards in the acquisition of human and animal tissues used for the isolation of primary cells and other biological materials. It also treats its cells with tremendous care and abides by strict cryopreservation protocol, so clients have the confidence that cell viability won’t be an issue upon proper thaw. What the client needs from the raw source material is skilfully extracted and what they don’t need is left out, so what they receive is a cellular product that’s been proficiently isolated to specifications best suited for their study. Additionally, iQ Biosciences understands that its cellular products can be used in a variety of applications, so it provides relevant donor data for each product, which may be vital to the client’s experimental needs. This includes HLA genotyping, immunophenotyping, and functional data to name a few, all available on the Certificate of Analysis that ships with each product. Ultimately, iQ Biosciences is passionate about the quality of its products, but more importantly, it cares intensely about supporting its clients. Its clients can rest assured that if they ever encounter a problem with one of iQ Biosciences’ products, they can provide the details and it will investigate with its utmost ability. Company: iQ Biosciences Contact: Chris Ng Email: [email protected] Website: